NBIX
NASDAQ · Biotechnology
Neurocrine Biosciences Inc
$164.63
+4.87 (+3.05%)
Financial Highlights (FY 2026)
Revenue
2.78B
Net Income
465.46M
Gross Margin
98.2%
Profit Margin
16.7%
Rev Growth
+24.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 98.2% | 98.2% | 30.1% | 30.1% |
| Operating Margin | 21.6% | 19.5% | 12.0% | 12.6% |
| Profit Margin | 16.7% | 15.9% | 9.0% | 10.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.78B | 2.24B | 5.53B | 5.58B |
| Gross Profit | 2.73B | 2.20B | 1.67B | 1.68B |
| Operating Income | 602.01M | 435.82M | 665.45M | 705.45M |
| Net Income | 465.46M | 336.96M | 497.45M | 570.29M |
| Gross Margin | 98.2% | 98.2% | 30.1% | 30.1% |
| Operating Margin | 21.6% | 19.5% | 12.0% | 12.6% |
| Profit Margin | 16.7% | 15.9% | 9.0% | 10.2% |
| Rev Growth | +24.3% | +24.3% | -8.7% | -7.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 3.03B | 2.43B |
| Total Equity | — | — | 6.26B | 6.50B |
| D/E Ratio | — | — | 0.48 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 627.39M | 479.42M | 909.27M | 972.70M |
| Free Cash Flow | — | — | 422.12M | 662.00M |